Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Department of Clinical Biochemistry and Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
JAMA Netw Open. 2020 Jul 1;3(7):e2013880. doi: 10.1001/jamanetworkopen.2020.13880.
During the ongoing coronavirus disease 2019 pandemic, case reports have suggested that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may lead to adverse outcomes.
To study the association of NSAID use with adverse outcomes in patients hospitalized with influenza or influenza pneumonia.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study used propensity score matching among 7747 individuals aged 40 years or older who were hospitalized with influenza, confirmed by polymerase chain reaction or antigen testing, between 2010 and 2018. Data were collected using Danish nationwide registers. All analyses reported were performed on May 29, 2020.
Prescription fill of an NSAID within 60 days before admission.
Risk ratio (RR) and risk difference (RD) with 95% CIs for intensive care unit admission and death within 30 days of admission.
A total of 7747 patients (median [interquartile range] age, 71 [59-80] years, 3980 [51.4%] men) with confirmed influenza were identified. Of these, 520 (6.7%) were exposed to NSAIDs. In the unmatched cohorts, 104 of 520 patients (20.0%) who used NSAIDs and 958 of 7227 patients (13.3%) who did not use NSAIDs were admitted to the intensive care unit. For death within 30 days of admission, we observed 37 events (7.1%) among those who used NSAIDs compared with 563 events (7.8%) among those who did not. Current NSAID use was associated with intensive care unit admission (RR, 1.51; 95% CI, 1.26 to 1.81; RD, 6.7%; 95% CI, 3.2% to 10.3%), while NSAID use was not associated with death (RR, 0.91; 95% CI, 0.66 to 1.26; RD, -0.7%; 95% CI, -3.0% to 1.6%). In the matched cohorts, risks were unchanged for patients who used NSAIDs, while 83 ICU admissions (16.0%) and 36 deaths (6.9%) were observed among matched individuals who did not use NSAIDs. Matched (ie, adjusted) analyses yielded attenuated risk estimates for intensive care unit admission (RR, 1.25; 95% CI, 0.95 to 1.63; RD, 4.0%; 95% CI, -0.6% to 8.7%) and death (RR, 1.03; 95% CI, 0.66 to 1.60; RD, 0.2%; 95% CI, -2.9% to 3.3%). Associations were more pronounced among patients who used NSAIDs for a longer period (eg, for intensive care unit admission: RR, 1.90; 95% CI, 1.19 to 3.06; RD, 13.4%; 95% CI, 4.0% to 22.8%).
In this cohort study of adult patients hospitalized with influenza, the use of NSAIDs was not associated with 30-day intensive care unit admission or death in adjusted analyses. There was an association between long-term use of NSAIDs and intensive care unit admission.
在当前的 2019 年冠状病毒病大流行期间,有病例报告表明,使用非甾体抗炎药(NSAIDs)可能导致不良后果。
研究 NSAIDs 使用与因流感或流感肺炎住院的患者不良结局之间的关联。
设计、地点和参与者:本队列研究使用了丹麦全国性登记处的数据,对 2010 年至 2018 年期间通过聚合酶链反应或抗原检测确诊的 7747 名年龄在 40 岁或以上的流感住院患者进行了倾向评分匹配。所有分析均于 2020 年 5 月 29 日进行。
入院前 60 天内开具 NSAIDs 处方。
30 天内入住重症监护病房和死亡的风险比(RR)和风险差(RD)。
共确定了 7747 名(中位数[四分位间距]年龄,71[59-80]岁,3980[51.4%]为男性)确诊流感的患者。其中 520 名(6.7%)暴露于 NSAIDs。在未匹配的队列中,使用 NSAIDs 的 520 名患者中有 104 名(20.0%)和未使用 NSAIDs 的 7227 名患者中有 958 名(13.3%)入住重症监护病房。在 30 天内死亡方面,我们观察到使用 NSAIDs 的患者中有 37 例(7.1%),而未使用 NSAIDs 的患者中有 563 例(7.8%)。当前 NSAID 使用与入住重症监护病房相关(RR,1.51;95%CI,1.26 至 1.81;RD,6.7%;95%CI,3.2%至 10.3%),而 NSAID 使用与死亡无关(RR,0.91;95%CI,0.66 至 1.26;RD,-0.7%;95%CI,-3.0%至 1.6%)。在匹配队列中,使用 NSAIDs 的患者风险无变化,而未使用 NSAIDs 的匹配个体中有 83 例入住重症监护病房(16.0%)和 36 例死亡(6.9%)。匹配(即调整)分析得出的重症监护病房入住风险估计值减弱(RR,1.25;95%CI,0.95 至 1.63;RD,4.0%;95%CI,-0.6%至 8.7%)和死亡(RR,1.03;95%CI,0.66 至 1.60;RD,0.2%;95%CI,-2.9%至 3.3%)。在 NSAIDs 使用时间较长的患者中,相关性更为明显(例如,重症监护病房入住:RR,1.90;95%CI,1.19 至 3.06;RD,13.4%;95%CI,4.0%至 22.8%)。
在这项对因流感住院的成年患者进行的队列研究中,调整分析显示 NSAIDs 使用与 30 天内入住重症监护病房或死亡无关。长期使用 NSAIDs 与入住重症监护病房之间存在关联。